A mixed Ca2+ channel blocker, A-1264087, utilizes peripheral and spinal mechanisms to inhibit spinal nociceptive transmission in a rat model of neuropathic pain

J Neurophysiol. 2014 Jan;111(2):394-404. doi: 10.1152/jn.00463.2013. Epub 2013 Oct 23.

Abstract

N-, T- and P/Q-type voltage-gated Ca(2+) channels are critical for regulating neurotransmitter release and cellular excitability and have been implicated in mediating pathological nociception. A-1264087 is a novel state-dependent blocker of N-, T- and P/Q-type channels. In the present studies, A-1264087 blocked (IC50 = 1.6 μM) rat dorsal root ganglia N-type Ca(2+) in a state-dependent fashion. A-1264087 (1, 3 and 10 mg/kg po) dose-dependently reduced mechanical allodynia in rats with a spinal nerve ligation (SNL) injury. A-1264087 (4 mg/kg iv) inhibited both spontaneous and mechanically evoked activity of spinal wide dynamic range (WDR) neurons in SNL rats but had no effect in uninjured rats. The inhibitory effect on WDR neurons remained in spinally transected SNL rats. Injection of A-1264087 (10 nmol/0.5 μl) into the spinal cord reduced both spontaneous and evoked WDR activity in SNL rats. Application of A-1264087 (300 nmol/20 μl) into the receptive field on the hindpaw attenuated evoked but not spontaneous firing of WDR neurons. Using electrical stimulation, A-1264087 (4 mg/kg iv) inhibited Aδ- and C-fiber evoked responses and after-discharge of WDR neurons in SNL rats. These effects by A-1264087 were not present in uninjured rats. A-1264087 moderately attenuated WDR neuron windup in both uninjured and SNL rats. In summary, these results indicate that A-1264087 selectively inhibited spinal nociceptive transmission in sensitized states through both peripheral and central mechanisms.

Keywords: N-type Ca2+ channels; P/Q-type Ca2+ channels; T-type Ca2+ channels; neuropathic pain; spinal cord.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials
  • Administration, Cutaneous
  • Anesthetics / administration & dosage
  • Anesthetics / pharmacology*
  • Anesthetics / therapeutic use
  • Animals
  • Azabicyclo Compounds / pharmacology*
  • Azabicyclo Compounds / therapeutic use
  • Calcium Channel Blockers / administration & dosage
  • Calcium Channel Blockers / pharmacology*
  • Calcium Channel Blockers / therapeutic use
  • Dose-Response Relationship, Drug
  • Hyperalgesia / drug therapy
  • Hyperalgesia / physiopathology
  • Inhibitory Concentration 50
  • Injections, Spinal
  • Leucine / analogs & derivatives*
  • Leucine / pharmacology
  • Leucine / therapeutic use
  • Male
  • Neuralgia / drug therapy
  • Neuralgia / physiopathology*
  • Neurons / drug effects
  • Neurons / physiology
  • Nociception / drug effects*
  • Peripheral Nerves / drug effects*
  • Peripheral Nerves / physiology
  • Rats
  • Rats, Sprague-Dawley
  • Spinal Nerves / drug effects*
  • Spinal Nerves / physiology

Substances

  • Anesthetics
  • Azabicyclo Compounds
  • Calcium Channel Blockers
  • N2-methyl-N-((2-(4-(trifluoromethyl)phenyl)octahydrocyclopenta(c)pyrrol-4-yl)leucinamide
  • Leucine